0001415889-24-003857.txt : 20240214
0001415889-24-003857.hdr.sgml : 20240214
20240214195910
ACCESSION NUMBER: 0001415889-24-003857
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240212
FILED AS OF DATE: 20240214
DATE AS OF CHANGE: 20240214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Overdorf Michael
CENTRAL INDEX KEY: 0001818522
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39402
FILM NUMBER: 24641578
MAIL ADDRESS:
STREET 1: C/O ANNEXON, INC.
STREET 2: 180 KIMBALL WAY, SUITE 200
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Annexon, Inc.
CENTRAL INDEX KEY: 0001528115
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 275414423
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1400 SIERRA POINT PARKWAY
STREET 2: BLDG C, SUITE 200
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: (650)-822-5500
MAIL ADDRESS:
STREET 1: 1400 SIERRA POINT PARKWAY
STREET 2: BLDG C, SUITE 200
CITY: BRISBANE
STATE: CA
ZIP: 94005
4
1
form4-02152024_120202.xml
X0508
4
2024-02-12
0001528115
Annexon, Inc.
ANNX
0001818522
Overdorf Michael
C/O ANNEXON, INC
1400 SIERRA POINT PKWY, BLDG C, STE 200
BRISBANE
CA
94005
false
true
false
false
EVP & CHIEF BUSINESS OFFICER
0
Common Stock
2024-02-12
4
S
0
1349
5.53
D
48592
D
The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").
This transaction was executed in multiple trades in prices ranging from $5.33 to $5.715, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Includes 29,392 RSUs.
Includes 4,139 shares acquired on November 15, 2023, pursuant to the Issuer's Employee Stock Purchase Plan.
/s/ Jennifer Lew, Attorney-in-Fact
2024-02-14